Solving neurodegeneration: common mechanisms and strategies for new treatments

Lauren K Wareham1, Shane A Liddelow2, Sally Temple3

  • 1Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA.

Insights

Common mechanisms in neurodegenerative diseases offer new therapeutic targets for neuronal protection and regeneration. Experts convened to discuss innovative treatments for conditions like glaucoma, focusing on shared roots in neuroinflammation and metabolism.

Area of Science:

  • Neuroscience
  • Ophthalmology
  • Genetics

Background:

  • Neurodegenerative diseases share common pathological mechanisms.
  • Glaucoma, a leading cause of blindness, involves optic nerve degeneration.
  • Identifying shared mechanisms can reveal cross-disease therapeutic targets.

Purpose of the Study:

  • To explore common mechanistic roots of neurodegenerative diseases.
  • To discuss emerging and innovative treatments for neurodegeneration.
  • To identify promising therapeutic targets for conditions including glaucoma.

Main Methods:

  • A virtual think-tank meeting titled "Solving Neurodegeneration" was convened in April 2021.
  • Key opinion leaders and experts in neurodegenerative disease participated.
  • Discussions focused on mechanistic overlap and treatment strategies.

Main Results:

  • Identified key areas of mechanistic overlap: neuroinflammation, bioenergetics/metabolism, genetics, and neurovascular interactions.
  • Highlighted innovative and promising research areas requiring further development.
  • Emphasized opportunities for collaboration to advance neuroprotection and regeneration.

Conclusions:

  • Understanding shared mechanisms across neurodegenerative diseases is crucial for developing novel therapies.
  • Targeting common pathways offers a promising strategy for preventing neurodegeneration and vision loss.
  • Further research and collaboration are essential to translate findings into effective treatments.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
276
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
778
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
709
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
415